CJC-1295 & Ipamorelin
Peptide signaling | GH • IGF-1 • Human evidence
Common names: CJC-1295 · CJC 1295 · CJC-1295 with DAC · CJC-1295 No DAC · CJC/IPA · CJC Ipamorelin · ipamorelin · growth hormone secretagogue
- Evidence searched through
- August 24, 2026
- Last reviewed
- August 24, 2026
- Current version
- 1.0
4V Take
What the research shows.
This is a good example of why details matter. Human studies show that long-acting CJC-1295 and ipamorelin can each affect growth-hormone signaling. But the popular CJC-1295 No DAC + ipamorelin combination has not been well studied in humans. Claims about better muscle, fat loss, recovery, sleep or longevity are still largely unproven for the combination.
Explore the evidenceResearch Interest
Why are people interested?
Researchers are studying CJC-1295 & Ipamorelin across the approved public questions in this record. Those questions are areas of research interest, not guaranteed outcomes.
Evidence Context
What have researchers looked at?
This approved record brings together the research settings represented in its selected public sources. Evidence settings answer different questions, so human, animal, laboratory, and research-review findings stay distinct.
Current research context
Research stage describes the maturity of the current topic record. Source context describes the evidence settings represented in the selected public sources below; they are not interchangeable.
- Research stage
- Exploratory / Early Clinical
- Selected source context
- Human · Mixed · Research Review
At a Glance
Research snapshot.
- 01Human Research
Separate PK/PD studies - 02Research Stage
Exploratory / Early Clinical - 03Key Distinction
DAC ≠ No DAC - 04Combination Outcomes
Not established
Research Pathway
Follow the questions.
Choose a pathway to read its approved 4V Take. Each view stays focused on one question at a time.
4V Take
Long-acting CJC-1295 with drug-affinity-complex technology increased GH and IGF-1 in healthy adults.
- Evidence bucket
- human clinical
- Research stage
- exploratory human
- Route / format
- Not applicable
Explore the evidence
human direct
Teichman SL et al. Prolonged stimulation of GH and IGF-I secretion by CJC-1295 in healthy adults. J Clin Endocrinol Metab. 2006.
human synthesis
Injectable Peptide Therapy primer/review, including CJC-1295 + ipamorelin evidence limitations.
human direct
Gobburu JV et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin in human volunteers. Pharm Res. 1999.
4V Take
The classic human CJC-1295 trial does not establish equivalent pharmacology or outcomes for “CJC-1295 No DAC.”
- Evidence bucket
- mixed
- Research stage
- exploratory human
- Route / format
- Not applicable
Explore the evidence
human direct
Teichman SL et al. Prolonged stimulation of GH and IGF-I secretion by CJC-1295 in healthy adults. J Clin Endocrinol Metab. 2006.
human direct
Gobburu JV et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin in human volunteers. Pharm Res. 1999.
human direct
Randomized proof-of-concept ipamorelin postoperative ileus trial.
4V Take
Ipamorelin stimulates GH release in healthy human volunteers.
- Evidence bucket
- human clinical
- Research stage
- exploratory human
- Route / format
- Not applicable
Explore the evidence
human direct
Gobburu JV et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin in human volunteers. Pharm Res. 1999.
human direct
Randomized proof-of-concept ipamorelin postoperative ileus trial.
human synthesis
Injectable Peptide Therapy primer/review, including CJC-1295 + ipamorelin evidence limitations.
4V Take
Ipamorelin did not demonstrate significant efficacy for postoperative ileus in a 114-person randomized proof-of-concept trial.
- Evidence bucket
- human clinical
- Research stage
- exploratory human
- Route / format
- Not applicable
Explore the evidence
human direct
Teichman SL et al. Prolonged stimulation of GH and IGF-I secretion by CJC-1295 in healthy adults. J Clin Endocrinol Metab. 2006.
human direct
Gobburu JV et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin in human volunteers. Pharm Res. 1999.
human direct
Randomized proof-of-concept ipamorelin postoperative ileus trial.
4V Take
Direct human evidence for the CJC-1295 No DAC + ipamorelin combination on muscle gain, fat loss, recovery, sleep, or longevity is not established.
- Evidence bucket
- mixed
- Research stage
- exploratory human
- Route / format
- Not applicable
Explore the evidence
human synthesis
Injectable Peptide Therapy primer/review, including CJC-1295 + ipamorelin evidence limitations.
human direct
Teichman SL et al. Prolonged stimulation of GH and IGF-I secretion by CJC-1295 in healthy adults. J Clin Endocrinol Metab. 2006.
human direct
Gobburu JV et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin in human volunteers. Pharm Res. 1999.
4V Take
Raising GH/IGF-1 is a pharmacodynamic effect, not proof of meaningful performance, body-composition, recovery, or anti-aging benefit.
- Evidence bucket
- mixed
- Research stage
- exploratory human
- Route / format
- Not applicable
Explore the evidence
human direct
Teichman SL et al. Prolonged stimulation of GH and IGF-I secretion by CJC-1295 in healthy adults. J Clin Endocrinol Metab. 2006.
human direct
Gobburu JV et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin in human volunteers. Pharm Res. 1999.
human direct
Randomized proof-of-concept ipamorelin postoperative ileus trial.
Selected Sources
Explore the evidence.
Open an approved public source to inspect its study context, limitations, and original record where available.
human direct
Teichman SL et al. Prolonged stimulation of GH and IGF-I secretion by CJC-1295 in healthy adults. J Clin Endocrinol Metab. 2006.
2006 · PMID: 16352683 · peer reviewed
human direct
Gobburu JV et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin in human volunteers. Pharm Res. 1999.
1999 · PMID: 10496658 · peer reviewed
human direct
Randomized proof-of-concept ipamorelin postoperative ileus trial.
2014 · PMID: 25331030 · peer reviewed
human synthesis
Injectable Peptide Therapy primer/review, including CJC-1295 + ipamorelin evidence limitations.
2026 · PMID: 41476424 · peer reviewed
human synthesis
2026 GH-IGF1 performance-enhancing peptide review. PubMed search record.
2026 · URL: https://pubmed.ncbi.nlm.nih.gov/?term=CJC-1295+without+DAC · peer reviewed
regulatory/contextual
WADA 2026 Prohibited List.
2026 · URL: https://www.wada-ama.org/en/resources/world-anti-doping-program/prohibited-list · contextual
Research Status
Living research, deliberately tracked.
- Evidence searched globally through:
- August 24, 2026
- Last reviewed
- August 24, 2026
- Version
- 1.0
What Changed
Current record.
No later approved public release is available beyond the current topic record.
Evidence Boundaries
What are researchers still working out?
Study settings, measures, and limitations matter. A mechanism does not establish an outcome, animal or laboratory findings do not establish a human benefit, and a small study does not create consensus. Open each selected source for the approved record behind its finding.
Regulatory Context
Context, not a shortcut.
This topic’s selected public record includes regulatory or other context sources. They can help explain the setting in which research is discussed, but regulatory status does not by itself prove or disprove scientific value. Open the original source for its exact context.
Save / Follow
Keep this research close.
Save and Follow remain private account preferences. Following does not activate monitoring or notifications.
Loading member research actions.